IntraBio Inc

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)

https://www.accesswire.com/viewarticle.aspx?id=660477&token=zoc8r6htwe590aibi81f

IntraBio Reports Statistically Significant and Clinically Meaningful Improvements in the Use of IB1001 For Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) Multinational clinical trial is the first successful clinical trial for GM2 Gangliosidosis; favourable safety and efficacy data consistent with previously announced IB1001 clinical trial results for NPC OXFORD, UK / ACCESSWIRE / August 19, 2021 / IntraBio Inc today announced positive data from its m...

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C

https://www.accesswire.com/viewarticle.aspx?id=608280

www.accesswire.com

IntaBio Neuroprotection and Disease Modification for Niemann-Pick C Extension Phase Approved in Europe

https://www.accesswire.com/573154/IntraBio-Neuroprotection-and-Disease-Modification-for-Niemann-Pick-C-Extension-Phase-Approved-in-Europe

IntraBio Neuroprotection and Disease Modification for Niemann-Pick C Extension Phase Approved in Europe OXFORD, UK / ACCESSWIRE / January 15, 2020 / IntraBio Inc., a late-stage biopharmaceutical company, is pleased to share that the Extension Phase for the IB1001-201 Clinical Trial has been approved in all European countries where the trial is being conducted. IB1001-201 is a multinational, clinical t...

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia

https://www.accesswire.com/538752/IntraBio-Investigational-New-Drug-Application-Approved-by-the-FDA-for-the-Treatment-of-Ataxia-Telangiectasia

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia OXFORD, UK / ACCESSWIRE / March 13, 2019 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for Clinical Trial IB1001-203 with its lead compound (IB1001) for the treatment...

IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C

https://www.accesswire.com/538583/IntraBio-Clinical-Trial-Authorisation-Application-Approved-by-the-MHRA-for-the-treatment-of-Niemann-Pick-Disease-Type-C

IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C OXFORD, UK / ACCESSWIRE / March 11, 2019 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compoun...

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C

https://www.accesswire.com/535211/IntraBio-Investigational-New-Drug-Application-Approved-by-the-FDA-for-the-Treatment-of-Niemann-Pick-Disease-Type-C

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C OXFORD, UK / ACCESSWIRE / February 13, 2019 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatm...

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease

https://www.accesswire.com/534958/IntraBio-Investigational-New-Drug-Application-Approved-by-the-FDA-for-the-Treatment-of-Tay-Sachs-and-Sandhoff-Disease

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease OXFORD, UK / ACCESSWIRE / February 11, 2019 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for Clinical Trial IB1001-202 involving its lead compound (IB1001) for the t...

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000

https://www.accesswire.com/532110/IntraBio-Receives-Niemann-Pick-Disease-European-Orphan-Drug-Designation-for-IB4000

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 OXFORD, UK / ACCESSWIRE / January 9, 2019 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation to IB4000 for the treatment of....

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000

https://www.accesswire.com/530834/IntraBio-Receives-Niemann-Pick-Disease-Orphan-Drug-Designation-from-the-FDA-for-IB4000

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 OXFORD, UK / ACCESSWIRE / December 19, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare (''orphan'') and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to IB4000 for the t...

IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA

https://www.accesswire.com/530328/IntraBio-Receives-Tay-Sachs-and-Sandhoff-Rare-Pediatric-Disease-Designation-from-the-FDA

IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA OXFORD, UK / ACCESSWIRE / December 12, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) t...

IntraBio is pleased to announce that our lead drug series IB1000s has been granted Orphan Drug Designation by the FDA for the treatment of Spinocerebellar Ataxia.

https://www.accesswire.com/530119/IntraBio-Receives-Spinocerebellar-Ataxia-Orphan-Drug-Designation-from-the-FDA

IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA OXFORD, UK / ACCESSWIRE / December 10, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its lead compound....

IntraBio Receives Spinocerebellar Ataxia European Orphan Drug Designation

https://www.accesswire.com/529750/IntraBio-Receives-Spinocerebellar-Ataxia-European-Orphan-Drug-Designation

IntraBio Receives Spinocerebellar Ataxia European Orphan Drug Designation OXFORD, UK / ACCESSWIRE /December 5, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series (I...

IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series

https://www.accesswire.com/529563/IntraBio-Receives-Niemann-Pick-Disease-Rare-Pediatric-Disease-Designation-from-the-FDA-for-IB1000-Series

IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series OXFORD, UK / ACCESSWIRE / December 3, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to...

IntraBio Announces Clinical Results for Treatment of Dementia

https://www.accesswire.com/viewarticle.aspx?id=529134

IntraBio Receives Tay-Sachs and Sandhoff Orphan Drug Designation from the FDA

https://www.accesswire.com/528978/IntraBio-Receives-Tay-Sachs-and-Sandhoff-Orphan-Drug-Designation-from-the-FDA

IntraBio Receives Tay-Sachs and Sandhoff Orphan Drug Designation from the FDA OXFORD, UK / ACCESSWIRE / November 26, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead com...

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB1000 Series

https://www.accesswire.com/528563/IntraBio-Receives-Niemann-Pick-Disease-Orphan-Drug-Designation-from-the-FDA-for-IB1000-Series

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB1000 Series OXFORD, UNITED KINGDOM / ACCESSWIRE / November 21, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its le...

IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).

https://www.accesswire.com/viewarticle.aspx?id=528310

IntraBio Receives Tay-Sachs and Sandhoff European Orphan Drug Designation OXFORD, UK / ACCESSWIRE / November 19, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series....

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB1000 Series.

https://www.accesswire.com/528044/IntraBio-Receives-Niemann-Pick-disease-European-Orphan-Drug-Designation-for-IB1000-Series?fbclid=IwAR0A6NvifbzmCOG072d-aREAJJ_XFuRxb2pqYzJOPxFpo_NT29pLZuYqhEE

IntraBio Receives Niemann-Pick disease European Orphan Drug Designation for IB1000 Series OXFORD, UK / ACCESSWIRE / November 14, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare "orphan" and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series (I...

IntraBio Inc updated their website address.